Weekly cisplatin, epirubicin, and paclitaxel with granulocyte colony-stimulating factor support vs triweekly epirubicin and paclitaxel in locally advanced breast cancer: final analysis of a sicog phase III study

The present study aimed at evaluating whether a weekly cisplatin, epirubicin, and paclitaxel (PET) regimen could increase the pathological complete response (pCR) rate in comparison with a tri-weekly epirubicin and paclitaxel administration in locally advanced breast cancer (LABC) patients. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Frasci, G, D'Aiuto, G, Comella, P, Thomas, R, Botti, G, Di Bonito, M, De Rosa, V, Iodice, G, Rubulotta, M R, Comella, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360722/
https://www.ncbi.nlm.nih.gov/pubmed/17047649
http://dx.doi.org/10.1038/sj.bjc.6603395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360722/
https://www.ncbi.nlm.nih.gov/pubmed/17047649
http://dx.doi.org/10.1038/sj.bjc.6603395

Ejemplares similares